2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium - Friday, November 13, 2020

Join us as we discuss today's pressing healthcare issues.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005244/en/

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

CO-HOSTS:

Bunny Ellerin

Director, HPM, Columbia Business School

Jing He

Biotech Analyst, Gabelli Funds

  • MBA, Harvard Business School
  • BA, Columbia University
  • MBA, Columbia Business School
  • MA, Washington University in St. Louis
  • BS, Peking University

Time

Agenda

9:00 – 9:10 AM

Welcome

  • Bunny Ellerin, Director, Healthcare and Pharmaceutical Management Program

9:10 – 10:00 AM

Vaccines & Therapeutics to Treat COVID-19

  • David Hering, Regional President, North America, Pfizer Vaccines
  • Dr. Robert Paris, Vice President, Infectious Diseases, Moderna
  • Dr. David Weinreich, Senior Vice President, Global Clinical Development, Regeneron
  • (Moderator) Jing He ‘15, Biotech Analyst, Gabelli Funds

10:10 – 11:00 AM

Health Policy & Reimbursement Trends

  • Dr. Deepa Kumaraiah, Senior Vice President, Service Lines and Chief Physician, NYP Medical Groups, NewYork-Presbyterian
  • Melissa Schulman, Senior Vice President of Government Affairs, CVS Health
  • Professor Michael Sparer, Chair, Health Policy and Management, Columbia University Mailman School of Public Health
  • (Moderator) Jeff Jonas, Portfolio Manager, Gabelli Funds

11:10 – Noon

Healthcare Delivery in a Virtual World

  • Dr. Amy Fahrenkopf, President, HSS Health and Senior Vice President, Hospital for Special Surgery
  • Jason Gorevic, CEO, Teladoc Health
  • Dr. Julie Silverstein, Divisional President, Oak Street Health
  • (Moderator) Kevin Kedra, Healthcare Analyst, G.research

Click Here to Register

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc. (NYSE: GBL).

Douglas R. Jamieson
914-921-5020
djamieson@gabelli.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

Agreement supports potential commercial readiness for Bria-IMT using Uneedle's proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell's pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026... Keep Reading...
InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of... Keep Reading...

Interactive Chart

Latest Press Releases

Related News